FDA — authorised 1 February 2023
- Marketing authorisation holder: GLAXOSMITHKLINE
- Status: approved
🇺🇸 Jesduvroq in United States
FDA authorised Jesduvroq on 1 February 2023
Marketing authorisations
FDA — authorised 1 February 2023
- Application: NDA216951
- Marketing authorisation holder: GLAXOSMITHKLINE
- Local brand name: JESDUVROQ
- Indication: TABLET — ORAL
- Status: approved
Jesduvroq in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in United States
Frequently asked questions
Is Jesduvroq approved in United States?
Yes. FDA authorised it on 1 February 2023; FDA authorised it on 1 February 2023.
Who is the marketing authorisation holder for Jesduvroq in United States?
GLAXOSMITHKLINE holds the US marketing authorisation.